Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD

MLA

De Dreuzy, Edouard, et al. “Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD.” Blood, vol. 136, no. 1, Number 1 Supplement 1, Nov. 2020, pp. 45–46. EBSCOhost, https://doi.org/10.1182/blood-2020-140073.

APA

De Dreuzy, E., Heath, J., Sousa, P., Janoudi, T., An, H., Hansen, S., Wood, D. K., Albright, C. F., Teixeira, S., Monesmith, T., Zhang, K., & Chang, K.-H. (2020). Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD. Blood, 136(1, Number 1 Supplement 1), 45–46. https://doi.org/10.1182/blood-2020-140073

Chicago

De Dreuzy, Edouard, Jack Heath, Patricia Sousa, Tusneem Janoudi, Harry An, Scott Hansen, David K. Wood, et al. 2020. “Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD.” Blood 136 (1, Number 1 Supplement 1): 45–46. doi:10.1182/blood-2020-140073.